CIDRAP newsletters options
Over half of adults diagnosed as having a rheumatologic disease reported persistent COVID-19 symptoms at least a month after recovery from their infection, according to survey results presented late last week at the virtual American College of Rheumatology annual meeting.
One study shows 85% protection against hospitalization.
In a trial, the oral drug Paxlovid reduced the risk of hospitalization or death by 89%.
Most pregnant women with a reported history of penicillin allergy who were tested were found not to be allergic and could tolerate penicillin during labor, according to a small retrospective study presented today at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI).
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
A detailed national survey of Americans, which included residents of the four largest US metropolitan areas, found that about half of those unwilling to be vaccinated against COVID-19 were unlikely to change their minds. A research team based at Emerson University published their findings yesterday in Scientific Reports.
More than 28 million extra years of life were lost among 31 well-off nations.
The plan will affect all employers with 100 or more employees, or 84 million Americans.
Officials warn that the continent could see another half million COVID-19 deaths by February.
The monetary benefit could be as high as $17 billion if vaccines are affordably priced, the report suggests.
A new report from the Centers for Disease Control and Prevention (CDC) shows that progress against healthcare-associated infections (HAIs), including those caused by antibiotic-resistant bacteria, took a step back in 2020.
The initial COVID-19 vaccine campaign in the United States was associated with fewer infections, emergency department (ED) visits, and hospitalizations among adults 65 and older, finds a study yesterday in The Lancet.
The high protection was found even amid high Alpha and Delta variant circulation.
Covaxin, made by Bharat Biotech, is an inactivated vaccine given in two doses 4 weeks apart.
COVID-19 didn't appear to spread efficiently within and among teams last fall.
"Please know we have conducted a thorough review of the safety data."
Spanish, Italian, and UK physicians reported high levels of depression and anxiety during the first two waves of the COVID-19 pandemic, finds a study yesterday in PLOS One.
Also, new CDC data show why immune-compromised people need an added COVID vaccine dose.
A hybrid of natural and vaccine immunity may protect better against breakthrough infections.
The ACIP recommendation now goes to CDC head Walensky for final approval.
